Table of Contents
ISRN Dermatology
Volume 2013 (2013), Article ID 125632, 4 pages
http://dx.doi.org/10.1155/2013/125632
Research Article

Endothelin-1 Levels in Scleroderma Patients: A Pilot Study

DISSAL, Section of Dermatology, IRCCS University Hospital San Martino-IST, 16132 Genoa, Italy

Received 28 May 2013; Accepted 10 July 2013

Academic Editors: S. Husz, E. Pasmatzi, P. D. Shenefelt, and Y. Tuzun

Copyright © 2013 Emanuele Cozzani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. K. Hummers and F. M. Wigley, “Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma,” Rheumatic Disease Clinics of North America, vol. 29, no. 2, pp. 293–313, 2003. View at Google Scholar · View at Scopus
  2. F. Hafner, G. Thomas, H. Froehlich, K. Steidl, and M. Brodmann, “Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers,” International Angiology, vol. 30, no. 5, pp. 493–495, 2011. View at Google Scholar · View at Scopus
  3. A. Balbir-Gurman and Y. Braun-Moscovici, “Scleroderma—new aspects in pathogenesis and treatment,” Best Practice and Research: Clinical Rheumatology, vol. 26, no. 1, pp. 13–24, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. B. White, E. A. Bauer, L. A. Goldsmith et al., “Guidelines for clinical trials in systemic sclerosis (scleroderma): I. Disease-modifying interventions,” Arthritis and Rheumatism, vol. 38, no. 3, pp. 351–360, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Kurgyis, R. Varga, I. Sick, M. U. Lang, T. Ruzicka, and M. Sárdy, “Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis,” Acta Dermato-Venereologica, vol. 91, no. 6, pp. 716–717, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Sulli, S. Soldano, C. Pizzorni et al., “Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis,” Journal of Rheumatology, vol. 36, no. 6, pp. 1235–1239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Parodi, P. Puiatti, and A. Rebora, “Serological profiles as prognostic clues for progressive systemic scleroderma: the Italian experience,” Dermatologica, vol. 183, no. 1, pp. 15–20, 1991. View at Google Scholar · View at Scopus
  8. J. H. Korn, M. Mayes, M. Matucci Cerinic et al., “Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 3985–3993, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Nagai, M. Hasegawa, T. Hattori, E. Okada, O. Tago, and O. Ishikawa, “Bosentan for digital ulcers in patients with systemic sclerosis,” Journal of Dermatology, vol. 39, no. 1, pp. 48–51, 2012. View at Publisher · View at Google Scholar · View at Scopus